Becton Dickinson and Co vs GE Vernova Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while GE Vernova Inc trades at $1,025.16 (market cap $263.90B). The key difference: GE Vernova Inc is far larger — about 5.4× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| BDX | GEV | |
|---|---|---|
Market Cap | $48.93B | $263.90B |
Sector | Health | Technology |
52-Week High | $185.39 | $1.17K |
52-Week Low | $138.62 | $547.96 |
Enterprise Value | $65.03B | $253.57B |
Dividend Yield | 2.34% | 0.2% |
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
GE Vernova (GEV) trades at $990.32, down 1.0% with bearish technical signals despite strong fundamentals. The company reported impressive Q1 2026 earnings beat but missed Q2 expectations, while maintaining robust profitability with 23.04% net margin and 91.48% ROE. Recent news highlights GEV's $176 billion backlog and positioning in AI-driven power infrastructure demand, though valuation metrics remain elevated with P/E of 28.41 and EV/EBITDA of 84.47.
Outlook remains positive with 75.86% analyst buy ratings and $1,270 consensus price target, representing 28% upside. Key opportunities include AI data center power demand and nuclear energy expansion, while risks include premium valuation sensitivity and execution challenges in managing rapid growth across energy segments.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →